Trial Profile

Efficacy of Canakinumab in Caucasian patients with Yao Syndrome: a retrospective, single centre study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Canakinumab (Primary)
Indications Familial autosomal dominant periodic fever
Focus Therapeutic Use

Most Recent Events

24 Nov 2018 New trial record
24 Oct 2018 Results assessing efficacy of canakinumab in patients with Yao syndrome, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com